Title |
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy
|
---|---|
Published in |
Molecular and Cellular Therapies, October 2014
|
DOI | 10.1186/2052-8426-2-32 |
Pubmed ID | |
Authors |
Mike-Andrew Westhoff, Georg Karpel-Massler, Oliver Brühl, Stefanie Enzenmüller, Katia La Ferla-Brühl, Markus D Siegelin, Lisa Nonnenmacher, Klaus-Michael Debatin |
Abstract |
Members of the PI3K/Akt/mTor signaling cascade are among the most frequently altered proteins in cancer, yet the therapeutic application of pharmacological inhibitors of this signaling network, either as monotherapy or in combination therapy (CT) has so far not been particularly successful. In this review we will focus on the role of PI3K/Akt/mTOR in two distinct tumors, Glioblastoma multiforme (GBM), an adult brain tumor which frequently exhibits PTEN inactivation, and Neuroblastoma (NB), a childhood malignancy that affects the central nervous system and does not harbor any classic alterations in PI3K/Akt signaling. We will argue that inhibitors of PI3K/Akt signaling can be components for potentially promising new CTs in both tumor entities, but further understanding of the signal cascade's complexity is essential for successful implementation of these CTs. Importantly, failure to do this might lead to severe adverse effects, such as treatment failure and enhanced therapy resistance. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 2% |
India | 1 | 2% |
Unknown | 49 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 16% |
Student > Master | 8 | 16% |
Student > Doctoral Student | 6 | 12% |
Student > Bachelor | 6 | 12% |
Researcher | 6 | 12% |
Other | 10 | 20% |
Unknown | 7 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 14 | 27% |
Medicine and Dentistry | 12 | 24% |
Biochemistry, Genetics and Molecular Biology | 6 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
Chemistry | 2 | 4% |
Other | 3 | 6% |
Unknown | 10 | 20% |